Tau protein levels in the cerebrospinal fluid of the patients with multiple sclerosis in an attack period: Low levels of tau protein may have significance, too.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical neurology and neurosurgery (Dutch-Flemish ed. Print)

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clineuro.2015.05.030PMID 26093227
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy

  2012cited by this paper
• Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis

  2012cited by this paper
• Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone

  2011cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse.

  2011cited by this paper
• Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

  2009cited by this paper
• Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis.

  2008cited by this paper
• Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.

  2008cited by this paper
• Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis

  2007cited by this paper
• Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

  2006cited by this paper
• The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

  2006cited by this paper
• Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

  2006cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.

  2005influential reference
• Tau, Phospho-Tau, and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis

  2005cited by this paper
• Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis

  2005cited by this paper
• Development of biomarkers in multiple sclerosis.

  2004cited by this paper
• Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG

  2004cited by this paper
• The 14-3-3 protein in multiple sclerosis: a marker of disease severity

  2004cited by this paper
• Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.

  2004cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• Manual of clinical laboratory immunology

  2002cited by this paper
• Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis

  2002cited by this paper
• Tau, where are we now?

  2002cited by this paper
• Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.

  2001cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• Increased Cerebrospinal Fluid Tau Protein in Multiple Sclerosis

  2000cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• Pilot Study of the Total and Phosphorylated Tau Proteins in Early-Stage Multiple Sclerosis

  2024cites this paper
• A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis

  2022influential citation
• The Role of Tau beyond Alzheimer’s Disease: A Narrative Review

  2022cites this paper
• Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis

  2021cites this paper
• Unsuspected Alzheimer disease in a patient with Multiple sclerosis and progressive aphasia.

  2020cites this paper
• An artificial intelligence process of immunoassay for multiple biomarkers based on logic gates.

  2020cites this paper
• Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop

  2020cites this paper
• Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis.

  2019cites this paper
• Controlled fluorescence quenching by antibody-conjugated graphene oxide to measure tau protein

  2018cites this paper
• Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system.

  2017cites this paper
• Science is 1% inspiration and 99% biomarkers

  2017cites this paper
• Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor.

  2017cites this paper
• Study of tear composition in multiple sclerosis patients

  year unknowncites this paper